Dr Kurt Miller from Berlin, Germany, looks ahead in prostate cancer. He reviews the drive for more personalised medicine and reviews biomarkers for partially prognostic and partially predictive markers, such as the composite score of LDH, neutrophil lymphocyte ratio and extent of metastases. He also considers the various genetic markers being explored, such as ERG. He then moves on to talk about potential new compounds, such as cabozantinib, OGX-011, PSMA ADC and bite molecules.

This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson